IP Library Patent Application 19195101
Patent Application
App. No. 19/195,101

SYSTEMS AND METHODS OF DIAGNOSING IDIOPATHIC PULMONARY FIBROSIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/195,101
Abstract

The present invention provides methods for sequencing and analysis of nucleic acids and determining that a subject is positive for a non-usual interstitial pneumonia subtype.

Claims (12)

1 . A method of detecting whether a lung tissue sample is positive for usual interstitial pneumonia (UIP) or non-usual interstitial pneumonia (non-UIP), comprising:

Assaying the expression level of each of a first group of transcripts and a second group of transcripts in a test sample of a subject, wherein the first group of transcripts includes one or more sequence corresponding to any one of the genes overexpressed in UIP and listed in any of Tables 5, 7, 9, 10, 11, and 12 and the second group of transcripts includes one or more sequence corresponding to any one of the genes under-expressed in UIP and listed in any of Tables 5, 8, 9, 10, 11, or 12; and

comparing the expression level of each of the first group of transcripts and the second group of transcripts with reference expression levels of the corresponding transcripts to (1) classify said lung tissue as usual interstitial pneumonia (UIP) if there is (a) an increase in an expression level corresponding to the first group and/or (b) a decrease in an expression level corresponding to the second group as compared to the reference expression levels, or (2) classify the lung tissue as non-usual interstitial pneumonia (non-UIP) if there is (c) an increase in the expression level corresponding to the second group and/or (d) a decrease in the expression level corresponding to the first group as compared to the reference expression levels.

2 . A method of detecting whether a lung tissue sample is positive for usual interstitial pneumonia (UIP) or non-usual interstitial pneumonia (non-UIP), comprising:

assaying by sequencing, array hybridization, or nucleic acid amplification the expression level of each of a first group of transcripts and a second group of transcripts in a test sample from a lung tissue of a subject, wherein the first group of transcripts includes one or more sequence corresponding to any one of the genes overexpressed in UIP and listed in any of Tables 5, 7, 9, 10, 1, and 12 and the second group of transcripts includes one or more sequence corresponding to any one of the genes under-expressed in UIP and listed in any of Tables 5, 8, 9, 10, 11, or 12; and

comparing the expression level of each of the first group of transcripts and the second group of transcripts with reference expression levels of the corresponding transcripts to (1) classify said lung tissue as usual interstitial pneumonia (UIP) if there is (a) an increase in an expression level corresponding to the first group and/or (b) a decrease in an expression level corresponding to the second group as compared to the reference expression levels, or (2) classify the lung tissue as non-usual interstitial pneumonia (non-UIP) if there is (c) an increase in the expression level corresponding to the second group and/or (d) a decrease in the expression level corresponding to the first group as compared to the reference expression levels.

3 . A method of detecting whether a lung tissue sample is positive for UIP or non-UIP, comprising: measuring the expression level of two or more transcripts expressed in the sample; and

using a computer generated classifier to classify the sample as UIP and non-UIP;

wherein the classifier was trained using a heterogeneous spectrum of non-UIP pathology subtypes comprising HP, NSIP, sarcoidosis, RB, bronchiolitis, and organizing pneumonia (OP).

4 . The method of claim 3 , wherein the test sample is a biopsy sample or a bronchoalveolar lavage sample.

5 . The method of claim 3 , wherein the test sample is fresh-frozen or fixed.

6 . The method of claims 3 , wherein the expression levels are determined by RT-PCR, DNA microarray hybridization, RNASeq, or a combination thereof.